Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | AXL amp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| AXL amp | lung non-small cell carcinoma | predicted - sensitive | Glesatinib | Phase I | Actionable | In a Phase I trial, a patient with non-small cell lung carcinoma harboring AXL amplification was sensitive to treatment with Glesatinib (MGCD265), demonstrating a 50% decrease in lesion size (PMID: 26555154). | 26555154 | |
| AXL amp | lung non-small cell carcinoma | predicted - sensitive | Glesatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Glesatinib (MGCD265) treatment resulted in partial responses (PR) as the best response in 9 of 49 evaluable patients with advanced solid tumors harboring MET or AXL alterations, including a PR lasting 3.5 years in a patient with AXL-amplified (CN 13) non-small cell lung cancer (PMID: 36459255; NCT00697632). | 36459255 |